Accepted Manuscripts                   Back to the articles list | Back to browse issues page

XML Print

Abstract:   (121 Views)
Introduction: Adipose-derived stem cells (ADSCs) are one of the most well-known and accessible sources of stem cells that can be used for the treatment of neurodegenerative diseases. On the other hand, previous studies have suggested that selegiline, as an irreversible inhibitor of monoamine oxidase, affects stem cells’ differentiation into neurons. This study was conducted to investigate the involvement in Phosphatidylinositol-bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in ADSCs differentiation to neuron-like cells using selegiline as inducer.
Methods: ADSCs were isolated from male rats, cultured in DMEM and then treated with selegiline (10-7 M) for 24hrs. Real-time PCR for nestin and neurofilament-68(NF-68) was performed from the negative control (ADSCs at the 3th passage), positive control (ADSCs were treated with 10-7 M selegeline for 24 hours), PI3AKT inhibitor (ADSCs were pretreated with treated with 10 µM LY294002 for 3 hours then10-7 M selegeline for next 24 hours), and MAPK inhibitor (ADSCs were pretreated with treated with 10 µM PD98059 for 3 hours then10-7 M selegeline for 24 next hours).
Results: Nestin and NF-68 genes have been overexpressed in the selegiline-treated ADSCs. PD98059 and LY294002 significantly down-regulated the selegiline-induced overexpression of nestin and NF-68, however PI3K inhibition did not return the genes expression to control level (p<0.05). ADSCs were immunoreactivefor nestin and NF-68 about 98% and 95% respectively.
Conclusion: According to the results, selegilinecan induce the gene expression of neural stem cell biomarkers in ADSCs through MAPK pathway activating and so differentiating them into neuron-like cells.
Types of Manuscript: Original Research | Subject: Cellular and Molecular BioMedicine

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.